SAN DIEGO--(BUSINESS WIRE)-- Biotheranostics, a leader in molecular diagnostics for cancer, today announced that Catherine Schnabel, Ph.D., Chief Scientific Officer, has been nominated for a 2016 Pinnacle Award by Athena, an organization dedicated to promoting the professional growth of women executives and managers in science and technology in San Diego.
Athena’s Pinnacle Awards recognize extraordinary women, men, companies/organizations, and educators who personify Athena San Diego’s mission of fostering the personal and professional growth of women through mentoring, education, recognition, and leadership training, thereby enhancing competitiveness and opportunity for women in the San Diego business community.
“We are pleased that Cathy Schnabel has been recognized by Athena for the significant role she plays in the development and advancement of skilled and talented women within our organization and the San Diego community,” said Nicolas Barthelemy, President and CEO of Biotheranostics. “We are proud of the fact that Biotheranostics offers a workplace where women can excel and thrive. About 80 percent of Biotheranostics’ executive team are women, versus about half for our overall employee population.”
Schnabel is an industry leader in the development of evidence-based diagnostics and in building clinical value for molecular tests. Since 2009, she has led the translational science and strategic programs for clinical development of Biotheranostics’ proprietary molecular diagnostics in oncology and genomic medicine. Schnabel has more than 15 years of experience as an industry scientist across pharmaceutical, clinical, and diagnostics research. She is a named co-inventor on several patents and has authored numerous publications.
Athena Pinnacle Awards are presented in five categories, including Life Sciences, Technology, Services, Education, and Company/Organization. Nominees and winners will be celebrated at the 18th Annual Pinnacle Awards dinner and auction April 28, 2016, at the Manchester Grand Hyatt in downtown San Diego.
Biotheranostics, Inc., is a leader in helping physicians improve the care of cancer patients, offering a suite of proprietary molecular diagnostic tests that allow treatment to be tailored to individual patients. The company’s CancerTYPE ID® is the most rigorously validated gene expression test for metastatic patients with diagnostic ambiguity, helping physicians determine optimal site-directed treatment regimens with the goal of improving patient outcomes. Its Breast Cancer IndexSM helps oncologists make difficult decisions about extended endocrine therapy for ER+ breast cancer patients based on its unique ability to predict risk of late disease recurrence and identify which patients are likely to benefit from continuing therapy beyond five years. Biotheranostics is based in San Diego. For more information, visit www.biotheranostics.com.